Acrivon Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Peter Blume-Jensen and 1 other reported changes in beneficial ownership of Acrivon Therapeutics, Inc. common stock on August 25, 2026.
NASDAQ
Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, Inc., sold 101 shares of common stock on August 18, 2026 for $2.01 per share.
NASDAQ
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc., sold 185 shares of common stock on August 18, 2026 for $2.01 per share.
NASDAQ
Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, Inc., sold 400 shares of common stock on August 18, 2026 for $2.01 per share.
NASDAQ
Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, Inc., sold 604 shares of common stock on August 18, 2026 for $2.01 per share.
NASDAQ
Peter Blume-Jensen and 1 other reported changes in beneficial ownership of Acrivon Therapeutics, Inc. common stock on August 18, 2026.
NASDAQ
Adam D. Levy, Chief Financial Officer of Acrivon Therapeutics, Inc., sold 1,142 shares of common stock on August 4, 2026 for $1.57 per share.
NASDAQ
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc., sold 573 shares of common stock on July 21, 2026 for $1.76 per share.
NASDAQ
Acrivon Therapeutics, Inc. executives Peter Blume-Jensen and Kristina Masson reported transactions related to their beneficial ownership of company stock.
NASDAQ
RA Capital Management reports a restricted stock unit grant to director Derek DiRocco for Acrivon Therapeutics, Inc.
NASDAQ
Michael John Tomsicek, a Director at Acrivon Therapeutics, Inc., acquired 9,366 restricted stock units (RSUs) on May 18, 2026.
NASDAQ
Acrivon Therapeutics Director Sharon Shacham acquired 9,366 restricted stock units (RSUs) on May 18, 2026, which are set to vest on May 18, 2027.
NASDAQ
Acrivon Therapeutics Director Palani Santhosh acquired 9,366 restricted stock units (RSUs) on May 18, 2026, which are set to vest on May 18, 2027.
NASDAQ
Director Ivana Magovcevic-Liebisch acquired 9,366 restricted stock units of Acrivon Therapeutics, Inc. (ACRV) on May 18, 2026, with full vesting expected on May 18, 2027.
NASDAQ
Derek DiRocco, a Director at Acrivon Therapeutics, Inc., acquired 9,366 restricted stock units (RSUs) on May 18, 2026, with full vesting scheduled for May 18, 2027.
NASDAQ
Charles M. Baum, a Director at Acrivon Therapeutics, Inc., acquired 9,366 restricted stock units (RSUs) on May 18, 2026, which are set to vest on May 18, 2027.
NASDAQ
Katharine Peterson, Chief Accounting Officer at Acrivon Therapeutics, acquired 14,227 shares of common stock through restricted stock units.
NASDAQ
Acrivon Therapeutics, Inc. reports a Form 4 filing detailing the acquisition of common stock by Chief Medical Officer, Mansoor Raza Mirza.
NASDAQ
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc., reported a disposition of 49,830 shares of common stock on May 18, 2026.
NASDAQ
Acrivon Therapeutics, Inc. Chief Financial Officer, Adam D. Levy, acquired 46,167 restricted stock units on May 18, 2026.
NASDAQ
Erick Gamelin, Chief Development Officer at Acrivon Therapeutics, Inc., acquired 38,584 shares of common stock.
NASDAQ
Acrivon Therapeutics Chief Operating Officer Eric Devroe reported a transaction involving 72,981 shares of common stock, acquired under a restricted stock unit plan.
NASDAQ
Acrivon Therapeutics, Inc. executives Peter Blume-Jensen and Kristina Masson have reported transactions involving restricted stock units and common stock.
NASDAQ
Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, Inc., reported a transaction involving the sale of common stock.
NASDAQ
Mary Miller, Chief Legal Officer at Acrivon Therapeutics, reported a transaction involving the sale of common stock.
NASDAQ
Erick Gamelin, Chief Development Officer at Acrivon Therapeutics, reported a transaction involving the sale of 404 shares of common stock.
NASDAQ
Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, Inc., reported a transaction involving the sale of common stock.
NASDAQ
Acrivon Therapeutics executives Peter Blume-Jensen and Kristina Masson reported transactions involving company common stock on May 14, 2026.
NASDAQ
RA Capital Management acquired 3,888,888 shares of Acrivon Therapeutics at $1.80 per share.
NASDAQ
Chief Legal Officer Mary Miller disposed of 558 shares of Acrivon Therapeutics to satisfy tax obligations upon RSU vesting.